Publications in 2024
A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.
Enshaei A, Joy M, Butler E, Kirkwood AA, Messina M, Pavoni C, Morgades M, Harrison CJ, Foà R, Ribera JM, Chiaretti S, Bassan R, Fielding AK, Moorman AV.

Blood Adv. 2024 Mar 12;8(5):1155-1166. doi: 10.1182/bloodadvances.2023011661. PMID: 38113467.

Publications in 2022
Neoadjuvant Chemotherapy in Locally Advanced Cervical Carcinoma - a Role in Patients with Para-aortic Lymph Node Involvement? A 10-year Institutional Experience.
Green HM, Counsell N, Ward A, McCormack M.

Clin Oncol (R Coll Radiol). 2022;34(7):e281-e90. 

Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.
Lechner M, Takahashi Y, Turri-Zanoni M, Liu J, Counsell N, Hermsen M, et al.
EurJ Cancer. 2022 Feb;162:221-236. 
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors.
Chan WY, Howells L, Wilson W, Sanchez E, Ainley L, Chavda SJ, Dowling E, Correia N, Lecat CSY, McMillan A, Wisniowski B, Mahmood S, Papanikolaou X, Lee L, Sive J, Kyriakou C, Wechalekar A, Popat R, Rabin N, Nastouli E, Yong KL, Xu K.
Br J Haematol. 2022Feb;196(3):e21-e26.

Results of a UK real world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory large B-cell lymphoma.
Northend M, Wilson W, Osborne W, Fox CP, Davies AJ, El-Sharkawi D, Phillips EH, Sim HW, Sadullah S, Shah N, Peng YY, Qureshi I, Addada J, Mora RF, Phillips N, Kuhnl A, Davies E, Wrench DJ, McKay P, Karpha I, Cowley A, Karim R, Challenor S, Singh V, Burton C, Auer R, Williams C, Cunningham J, Broom A, Arasaretnam A, Roddie C, Menne T, Townsend WM.
BloodAdv. 2022 Jan 12:bloodadvances.2021005953.
Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.
Kuhnl A, Roddie C, Kirkwood AA, Menne T, Cuadrado M, Marzolini MAV, Osborne W, Sanderson R, O'Reilly M, Townsend W, Benjamin R, Potter V, Patten PEM, Yallop D, Voo S, Petrides GS, Mulholland N, Kayani I.

BloodAdv. 2022 Jan 11;6(1):321-326

Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients.
Wilson MR, Eyre TA, Kirkwood AA, Wong Doo N, Soussain C, Choquet S, Martinez-Calle N, Preston G, Ahearne MJ, Schorb E, Moles-Moreau MP, Ku M, Rusconi C, Khwaja J, Narkhede M, Lewis KL, Calimeri T, Durot E, Renaud L, Øvlisen AK, Mcilroy G, Ebsworth TJ, Elliot J, Santarsieri A, Ricard L, Shah N, Liu Q, Zayac AS, Vassallo F, Lebras L, Roulin L, Lombion N, Manos K, Fernandez R, Hamad N, Lopez-Garcia A, O'Mahony D, Gounder P, Forgeard N, Lees C, Agbetiafa K, Strüessmann T, Htut TW, Clavert A, Scott H, Guidetti A, Barlow BR, Tchernonog E, Smith J, Miall F, Fox CP, Cheah CY, El Galaly TC, Ferreri AJM, Cwynarski K, McKay P.
Publications in 2021
. Impact of COVID-19 on peripheral blood stem cell mobilization for myeloma patients.
Camilleri M, McGrath T, Wilson W, Ings SJ, Horder J, Newrick F, Sive J, Papanikolaou X, Popat R, Kyriakou C, Yong K, Rabin N.
Leuk Lymphoma. 2021Dec;62(12):3023-3026.

Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies.
Fox TA, Kirkwood AA, Enfield L, O'Reilly M, Arulogun S, D'Sa S, O'Nions J, Kavi J, Vitsaras E, Townsend W, Burns SO, Gohil SH, Cwynarski K, Thomson KJ, Noursadeghi M, Heyderman RS, Rampling T, Ardeshna KM, McCoy LE, Morris EC.

BrJ Haematol. 2021 Dec;195(5):706-709.

Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experience.
Richards H, Chavda SJ, Wilson W, Camilleri M, Cohen O, Horder J, Newrick F, Papanikolaou X, Sive J, Lee L, Popat R, Wechalekar A, Kyriakou C, Yong K, Rabin N.
Leuk Lymphoma. 2021Dec;62(14):3544-3547.
Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma.
Rockall AG, Barwick TD, Wilson W, Singh N, Bharwani N, Sohaib A, Nobbenhuis M, Warbey V, Miquel M, Koh DM, De Paepe KN, Martin-Hirsch P, Ghaem-Maghami S, Fotopoulou C, Stringfellow H, Sundar S, Manchanda R, Sahdev A, Hackshaw A, Cook GJ; MAPPING Study Group.
Clin Cancer Res.2021 Dec 1;27(23):6457-6466.
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.
Lecat CSY, Taube JB, Wilson W, Carmichael J, Parrish C, Wallis G, Kyriakou C, Lee L, Mahmood S, Papanikolaou X, Rabin NK, Sive J, Wechalekar AD, Yong K, Cook G, Popat R.
Front Oncol. 2021 Jul21;11:703233.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.
Martinez-Calle N, Kirkwood AA, Lamb M, Smith A, Khwaja J, Manos K, Shrubsole C, Gray N, Lewis K, Tivey A, Bishton MJ, Hawkes E, Ahearne MJ, Osborne W, Collins GP, Illidge T, Linton KM, Cwynarski K, Burton C, Fox CP.
AdvTher. 2021 Jul;38(7):3789-3802.
Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.
Eyre TA, Wilson W, Kirkwood AA, Wolf J, Hildyard C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Kothari J, Fox CP, Martinez-Calle N, McMillan A, Bishton M, Collins GP, Hatton CSR.
BloodAdv. 2021 Apr 27;5(8):2229-2236. 
Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Lee L, Alrasheed N, Khandelwal G, Fitzsimons E, Richards H, Wilson W, Chavda SJ, Henry J, Conde L, De Massy MR, Chin M, Galas-Filipowicz D, Herrero J, Chain B, Quezada SA, Yong K.
Front Immunol. 2021Feb 25;12:618610.

Publications in 2020
Multimodal Treatment in Metastatic Colorectal Cancer (mCRC) Improves Outcomes-The University College London Hospital (UCLH) Experience.
Joharatnam-Hogan N, Wilson W, Shiu KK, Fusai GK, Davidson B, Hochhauser D, Bridgewater J, Khan K.
Cancers (Basel). 2020Nov 27;12(12):3545.
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.
Crolley VE, Hanna D, Joharatnam-Hogan N, Chopra N, Bamac E, Desai M, Lam YC, Dipro S, Kanani R, Benson J, Wilson W, Fox TA, Shiu KK, Forster M, Bridgewater J, Hochhauser D, Khan K.
Ther Adv Med Oncol.2020 Oct 23;12:1758835920971147.
Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer: a multi-centre North London experience.
Joharatnam-Hogan N, Hochhauser D, Shiu KK, Rush H, Crolley V, Wilson W, Sharma A, Muhammad A, Anwar M, Vasdev N, Goldstein R, Kantser G, Saha A, Raja F, Bridgewater J, Khan K.
Ther Adv Med Oncol.2020 Sep 14;12:1758835920956803.

Publications in 2019
Sequential screening for lung cancer in a high-risk group: randomised controlled trial: LungSEARCH: a randomised controlled trial of Surveillance using sputum and imaging for the EARly detection of lung Cancer in a High-risk group.
Stephen G. Spiro, Pallav L. Shah, Robert C. Rintoul, Jeremy George, Samuel Janes, Matthew Callister, Marco Novelli, Penny Shaw, Gabrijela Kocjan, Chris Griffiths, Mary Falzon, Richard Booton, Nicholas Magee, Michael Peake, Paul Dhillon, Kishore Sridharan, Andrew G. Nicholson, Simon Padley, Magali N. Taylor, Asia Ahmed, Jack Allen, Yenting Ngai, Nyasha Chinyanganya, Victoria Ashford-Turner, Sarah Lewis, Dahmane Oukrif, Pamela Rabbitts, Nicholas Counsell, Allan Hackshaw

Eur Respir J. 2019 Oct 17;54(4):1900581.

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Roeker, L. E., Fox, C. P., Eyre, T. A., Brander, D. M., Allan, J. N., Schuster, S. J., Nabhan, C., Hill, B. T., Shah, N. N., Lansigan, F., Yazdy, M., Cheson, B. D., Lamanna, N., Singavi, A. K., Coombs, C. C., Barr, P. M., Skarbnik, A. P., Shadman, M., Ujjani, C. S., Tuncer, H. H., Winter, A. M., Rhodes, J., Dorsey, C., Morse, H., Kabel, C., Pagel, J. M., Williams, A. M., Jacobs, R., Goy, A., Muralikrishnan, S., Pearson, L., Sitlinger, A., Bailey, N., Schuh, A., Kirkwood, A. A. and Mato, A. R.
Clin Cancer Res.2019 Jul 15;25(14):4264-4270 
Publications in 2011
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).
Lancet 2011; 378: 771–84.
Publications in 2007
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
LHRH-agonists in Early Breast Cancer Overview group
Lancet 2007; 369: 1711–1723
Publications in 2005
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
Lancet 2005; 365: 1687–1717
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us